J. Goldman & CO LP Bellus Health Inc. Call Options Transaction History

J. Goldman & CO LP

  • $3.21 Billion
  • Q3 2024

Call Options

1 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2021

Feb 14, 2022
BUY
$5.26 - $8.3 $191,990 - $302,950
36,500 New
36,500 $294,000

Others Institutions Holding BLU

# of Institutions
1
Shares Held
128K
Call Options Held
0
Put Options Held
0
View Full List

About BELLUS Health Inc.

BLU Quotes by TradingView
  • Ticker BLU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 125,793,000
  • Description
  • BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...
More about BLU
Track This Portfolio

Track J. Goldman & CO LP Portfolio

Follow J. Goldman & CO LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

News

Stay updated on J. Goldman & CO LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email